Skip to main content
HR 6576 115th Congress House Health Drug safety, medical device, and laboratory regulation Licensing and registrations Marketing and advertising

Drug-Price Transparency in Communications Act

Introduced: July 26, 2018 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 27, 2018
Referred to the Subcommittee on Health.
Jul 26, 2018
Referred to the House Committee on Energy and Commerce.
Jul 26, 2018
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.

What's happening now July 27, 2018

Referred to the Subcommittee on Health.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6576: Drug-Price Transparency in Communications Act. 115th Congress. Open America. https://openamerica.io/bill/115-HR-6576/
MLA
"H.R. 6576: Drug-Price Transparency in Communications Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-6576/.
Bluebook (legal)
H.R. 6576, 115th Cong. (2026), https://openamerica.io/bill/115-HR-6576/.
Markdown link
[H.R. 6576: Drug-Price Transparency in Communications Act](https://openamerica.io/bill/115-HR-6576/)
Report a problem